Literature DB >> 22481384

Study of LPIN1, LPIN2 and LPIN3 in rhabdomyolysis and exercise-induced myalgia.

Caroline Michot1, Laurence Hubert, Norma B Romero, Amr Gouda, Asmaa Mamoune, Suja Mathew, Edwin Kirk, Louis Viollet, Shamima Rahman, Soumeya Bekri, Heidi Peters, James McGill, Emma Glamuzina, Michelle Farrar, Maya von der Hagen, Ian E Alexander, Brian Kirmse, Magalie Barth, Pascal Laforet, Pascale Benlian, Arnold Munnich, Marc JeanPierre, Orly Elpeleg, Ophry Pines, Agnès Delahodde, Yves de Keyzer, Pascale de Lonlay.   

Abstract

BACKGROUND: Recessive LPIN1 mutations were identified as a cause of severe rhabdomyolysis in pediatric patients. The human lipin family includes two other closely related members, lipin-2 and 3, which share strong homology and similar activity. The study aimed to determine the involvement of the LPIN family genes in a cohort of pediatric and adult patients (n = 171) presenting with muscular symptoms, ranging from severe (CK >10 000 UI/L) or moderate (CK <10 000 UI/L) rhabdomyolysis (n = 141) to exercise-induced myalgia (n = 30), and to report the clinical findings in patients harboring mutations.
METHODS: Coding regions of LPIN1, LPIN2 and LPIN3 genes were sequenced using genomic or complementary DNAs.
RESULTS: Eighteen patients harbored two LPIN1 mutations, including a frequent intragenic deletion. All presented with severe episodes of rhabdomyolysis, starting before age 6 years except two (8 and 42 years). Few patients also suffered from permanent muscle symptoms, including the eldest ones (≥ 40 years). Around 3/4 of muscle biopsies showed accumulation of lipid droplets. At least 40% of heterozygous relatives presented muscular myalgia. Nine heterozygous SNPs in LPIN family genes were identified in milder phenotypes (mild rhabdomyolysis or myalgia). These variants were non-functional in yeast complementation assay based on respiratory activity, except the LPIN3-P24L variant.
CONCLUSION: LPIN1-related myolysis constitutes a major cause of early-onset rhabdomyolysis and occasionally in adults. Heterozygous LPIN1 mutations may cause mild muscular symptoms. No major defects of LPIN2 or LPIN3 genes were associated with muscular manifestations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22481384     DOI: 10.1007/s10545-012-9461-6

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  42 in total

1.  Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood.

Authors:  Avraham Zeharia; Avraham Shaag; Riekelt H Houtkooper; Tareq Hindi; Pascale de Lonlay; Gilli Erez; Laurence Hubert; Ann Saada; Yves de Keyzer; Gideon Eshel; Frédéric M Vaz; Ophry Pines; Orly Elpeleg
Journal:  Am J Hum Genet       Date:  2008-09-25       Impact factor: 11.025

2.  Lipin-1γ isoform is a novel lipid droplet-associated protein highly expressed in the brain.

Authors:  Huajin Wang; Jing Zhang; Wei Qiu; Gil-Soo Han; George M Carman; Khosrow Adeli
Journal:  FEBS Lett       Date:  2011-05-20       Impact factor: 4.124

3.  LPIN1 gene mutations: a major cause of severe rhabdomyolysis in early childhood.

Authors:  Caroline Michot; Laurence Hubert; Michèle Brivet; Linda De Meirleir; Vassili Valayannopoulos; Wolfgang Müller-Felber; Ramesh Venkateswaran; Hélène Ogier; Isabelle Desguerre; Cécilia Altuzarra; Elizabeth Thompson; Martin Smitka; Angela Huebner; Marie Husson; Rita Horvath; Patrick Chinnery; Frederic M Vaz; Arnold Munnich; Orly Elpeleg; Agnès Delahodde; Yves de Keyzer; Pascale de Lonlay
Journal:  Hum Mutat       Date:  2010-07       Impact factor: 4.878

4.  Rhabdomyolysis induced by co-administration of fluvastatin and colchicine.

Authors:  Filippo M Sarullo; Luigi Americo; Antonino Di Franco; Pietro Di Pasquale
Journal:  Monaldi Arch Chest Dis       Date:  2010-09

Review 5.  Statin-fibrate combination therapy.

Authors:  A Shek; M J Ferrill
Journal:  Ann Pharmacother       Date:  2001 Jul-Aug       Impact factor: 3.154

6.  Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway.

Authors:  Brian N Finck; Matthew C Gropler; Zhouji Chen; Teresa C Leone; Michelle A Croce; Thurl E Harris; John C Lawrence; Daniel P Kelly
Journal:  Cell Metab       Date:  2006-09       Impact factor: 27.287

7.  Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns.

Authors:  Jimmy Donkor; Meltem Sariahmetoglu; Jay Dewald; David N Brindley; Karen Reue
Journal:  J Biol Chem       Date:  2006-12-07       Impact factor: 5.157

8.  Adipose tissue lipin-1 expression is correlated with peroxisome proliferator-activated receptor alpha gene expression and insulin sensitivity in healthy young men.

Authors:  Jimmy Donkor; Lauren M Sparks; Hui Xie; Steven R Smith; Karen Reue
Journal:  J Clin Endocrinol Metab       Date:  2007-10-09       Impact factor: 5.958

9.  Clinical and genetic analysis of lipid storage myopathies.

Authors:  Aya Ohkuma; Satoru Noguchi; Hideo Sugie; May Christine V Malicdan; Tokiko Fukuda; Kunio Shimazu; Luis Carlos López; Michio Hirano; Yukiko K Hayashi; Ikuya Nonaka; Ichizo Nishino
Journal:  Muscle Nerve       Date:  2009-03       Impact factor: 3.217

10.  LPS and proinflammatory cytokines decrease lipin-1 in mouse adipose tissue and 3T3-L1 adipocytes.

Authors:  Biao Lu; Yang Lu; Arthur H Moser; Judy K Shigenaga; Carl Grunfeld; Kenneth R Feingold
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-10-21       Impact factor: 4.310

View more
  33 in total

1.  Lipin1 is required for skeletal muscle development by regulating MEF2c and MyoD expression.

Authors:  Abdulrahman Jama; Dengtong Huang; Abdullah A Alshudukhi; Roman Chrast; Hongmei Ren
Journal:  J Physiol       Date:  2018-12-26       Impact factor: 5.182

Review 2.  Mammalian lipin phosphatidic acid phosphatases in lipid synthesis and beyond: metabolic and inflammatory disorders.

Authors:  Karen Reue; Huan Wang
Journal:  J Lipid Res       Date:  2019-02-25       Impact factor: 5.922

3.  Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence.

Authors:  Liam R Brunham; Steven Baker; Andrew Mammen; G B John Mancini; Robert S Rosenson
Journal:  Cardiovasc Res       Date:  2018-07-01       Impact factor: 10.787

Review 4.  Neuromuscular and systemic presentations in adults: diagnoses beyond MERRF and MELAS.

Authors:  Bruce H Cohen
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

Review 5.  Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases.

Authors:  F Lamari; F Mochel; F Sedel; J M Saudubray
Journal:  J Inherit Metab Dis       Date:  2012-07-20       Impact factor: 4.982

6.  Lipin1 Regulates Skeletal Muscle Differentiation through Extracellular Signal-regulated Kinase (ERK) Activation and Cyclin D Complex-regulated Cell Cycle Withdrawal.

Authors:  Weihua Jiang; Jing Zhu; Xun Zhuang; Xiping Zhang; Tao Luo; Karyn A Esser; Hongmei Ren
Journal:  J Biol Chem       Date:  2015-08-20       Impact factor: 5.157

7.  An overview of inborn errors of complex lipid biosynthesis and remodelling.

Authors:  Foudil Lamari; Fanny Mochel; Jean-Marie Saudubray
Journal:  J Inherit Metab Dis       Date:  2014-09-20       Impact factor: 4.982

8.  Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle.

Authors:  Peixiang Zhang; M Anthony Verity; Karen Reue
Journal:  Cell Metab       Date:  2014-06-12       Impact factor: 27.287

Review 9.  Inborn errors of metabolism in the biosynthesis and remodelling of phospholipids.

Authors:  Saskia B Wortmann; Marc Espeel; Ligia Almeida; Annette Reimer; Dennis Bosboom; Frank Roels; Arjan P M de Brouwer; Ron A Wevers
Journal:  J Inherit Metab Dis       Date:  2014-09-02       Impact factor: 4.982

Review 10.  Lipins, lipinopathies, and the modulation of cellular lipid storage and signaling.

Authors:  Lauren S Csaki; Jennifer R Dwyer; Loren G Fong; Peter Tontonoz; Stephen G Young; Karen Reue
Journal:  Prog Lipid Res       Date:  2013-04-17       Impact factor: 16.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.